|Year : 2019 | Volume
| Issue : 2 | Page : 317-323
Receptors for advanced glycation end products is associated with autophagy in the clear cell renal cell carcinoma
Yong Guo1, Hai-Cong Zhang2, Sheng Xue3, Jun-Hua Zheng4
1 Department of Urology, Shanghai Tenth People's Hospital of Nanjing Medical University, Nanjing; Transplantation Centre, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
2 Department of Pathology, The Fifth Hospital of Shijiazhuang, Shijiazhuang, China
3 Department of Urology, Shanghai Tenth People's Hospital of Nanjing Medical University, Nanjing, China
4 Department of Urology, Shanghai General Hospital of Nanjing Medical University, Nanjing; Department of Urology, The Affiliated First People's Hospital of Shanghai Jiao Tong University, Shanghai, China
|Date of Web Publication||1-Apr-2019|
Dr. Jun-Hua Zheng
No. 101, Longmin Street, Nanjing Medical University, Jiangning, Nanjing 211166
Source of Support: None, Conflict of Interest: None
Background: The receptor for advanced glycation end-product (RAGE) was one of the signal transduction receptors. RAGE interacted with various signaling molecules which were involved in human disease processes including tumorigenesis. Previous reports have indicated that RAGE/high-mobility group box 1 (HMGB1) could regulate autophagy in different carcinomas. However, the functional role of RAGE/ HMGB1 in the regulation of clear cell renal cell carcinoma (ccRCC) autophagy remained unrevealed.
Methods: Western blot, quantitative real-time polymerase chain reaction (qRT-PCR) and immunofluorescence were used in the present study.
Results: In this study, we demonstrated that the levels of RAGE/HMGB1 and autophagic protein LC3, Beclin-1, PI3K were much higher in ccRCC samples than those of in adjacent normal tissues. RAGE and autophagic protein expression was regulated with RAGE/HMGB1 in human RCC cell lines.
Conclusion: Our results implicated that RAGE and autophagy played important roles in ccRCC, and RAGE/HMGB1 might serve as a novel therapeutic target for future ccRCC treatment.
Keywords: Autophagy, clear cell renal cell carcinoma, high-mobility group box 1, receptor for advanced glycation end-product
|How to cite this article:|
Guo Y, Zhang HC, Xue S, Zheng JH. Receptors for advanced glycation end products is associated with autophagy in the clear cell renal cell carcinoma. J Can Res Ther 2019;15:317-23
|How to cite this URL:|
Guo Y, Zhang HC, Xue S, Zheng JH. Receptors for advanced glycation end products is associated with autophagy in the clear cell renal cell carcinoma. J Can Res Ther [serial online] 2019 [cited 2020 Jun 3];15:317-23. Available from: http://www.cancerjournal.net/text.asp?2019/15/2/317/255085
| > Introduction|| |
The kidney is composed of heterogeneous populations of cells. These cells cooperate together and take part in a variety of complex and interdependent processes. Many studies have demonstrated that kidney diseases had a potential association with inflammation. Renal cell carcinoma (RCC) was a common urologic cancer. In 2014, it accounted for about 2%–3% of all malignancy cases in global adults. Moreover, the incidence of RCC has steadily increased in recent years. The surgical resection of RCC led to a 5-year survival of nearly 90%. Clear cell RCC (ccRCC) was one of the most common histological types of RCC, which accounted for about 70%–80% of the RCC. However, the exact cause and mechanism of the ccRCC development remained unrevealed. Therefore, it is urgent to investigate the pathogenesis of ccRCC in detail for better prevention and treatment. Recently, growing evidence demonstrated that tumor microenvironment (TME) contributed a lot to the progression of malignancy.
The receptor for advanced glycation end-product (RAGE) is one of the signal transduction receptors which interact with various downstream signaling molecules, including high-mobility group box 1 (HMGB1), S100/calgranulins, β-amyloid, AGEs, phosphatidylserine, C3a, and advanced oxidation protein products. RAGE has been reported to participate in a variety of human disease processes, such as diabetes, cardiovascular diseases, and cancers. The expression of RAGE is very low or even few in normal tissues. Nevertheless, the RAGE expression would be enhanced in cancer and chronic inflammation, enabled it a perfect predictor in the progression and prognosis of physical disorders, such as chronic inflammation and diabetic complications. However, until now, the precise contributions of RAGE in renal cancer remained unrevealed. Growing evidence demonstrated that RAGE was involved in the progression of various human cancers, including RCC, pancreatic cancer, prostate cancer, colon cancer, esophageal cancer, biliary cancer, gastric cancer, and lung cancer.,,,, Furthermore, the suppression of RAGE signaling has been applied to inhibit tumor proliferation, migration, and angiogenesis in various cancers.,,, Therefore, there is growing interest and urgent need to elucidate the intracellular pathways through which RAGE participated in these disease-related processes. RAGE was known to interact with a variety of signaling molecules. Earlier reports generally focused on inflammatory-associated pathways, such as the nuclear factor-kappa B (NFκB) and the mitogen-activated protein kinase (MAPK) signaling. Recently, it also confirmed that many innovative pathways would be activated on the stimulation of RAGE. One of these pathways was involved in autophagy, which devoted to the final effects of RAGE.
HMGB1 is a nuclear DNA binding protein which has been discovered more than 30 years ago. It was demonstrated to function as a potent proinflammatory cytokine. HMGB1 plays its roles through several cell-surface receptors including the toll-like receptors (TLRs) and RAGE. Studies have indicated that HMGB1 played critical roles in the pathogenesis of RCC and multiple kidney diseases.
Autophagy is a conserved process, in which cytoplasmic material is degraded by lysosomes or vacuoles and then recycled. It contributed to the recycling of metabolic substances and make effects on maintaining cellular homeostasis. Recent reports suggested that autophagy was a key factor for regulating cancer cell survival in human cancers. It allowed cells to survive in the hypoxic and nutrient-deprived TME. Therefore, RAGE-mediated autophagy may play critical roles in TME.
In this study, we demonstrated the relationship between HMGB1/RAGE and autophagy in ccRCC. We investigated the expression levels of HMGB1/RAGE, LC3, Beclin-1, and PI3K in ccRCC samples and adjacent normal tissues. The dysregulation of HMGB1/RAGE was found to be one of the major mechanisms leading to the autophagy in ccRCC. Our results presented novel insights into understanding the molecular mechanism of autophagy in ccRCC, which provided a future direction of interventional therapy for ccRCC.
| > Materials and Methods|| |
This research was reviewed and approved by the Ethics Committee of the first affiliated hospital of Wenzhou Medical University. The informed consents were obtained from all the patients. The whole procedure including specimen collection was harmless. The whole research conformed to the principles in the Declaration of Helsinki.
From January 2016 to July 2016, RCC tissues and paired adjacent nontumorous renal tissues (≥3 cm away from the tumor, confirming that no cancer cell was found in the tangent lines) were obtained from 12 patients with RCC, who received tumor nephrectomy at first affiliated hospital of Wenzhou Medical University. All specimens from nephrectomy were immediately snap-frozen in liquid nitrogen and stored at −80°C before the extraction of RNA and protein.
Western blot analysis
About 5 × 106 cells were collected after transfecting for 24 h. The cells were lysed in RIPA buffer (Cell Signaling Technology, Danvers, MA, USA) with the addition of protease inhibitor (phenylmethanesulfonyl fluoride) and phosphatase inhibitor (Na-orthovanadate and NaF). In brief, 8%–10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was applied fractionate equal amounts of total protein which was extracted from cells or tissues. The extracted total protein was electrically transferred onto polyvinylidene difluoride (PVDF) membranes. The PVDF membrane was first incubated with monoclonal antibody against RAGE (1:1000, Abcam), Beclin-1 (1:1000, Abcam), HMGB1 (1:1000, Abcam), LC3AB (1:1000, Abcam), PI3KC-3 (1:1000, Abcam) and GAPDH (1:2000, Boster), and then incubated with appropriate horseradish peroxidase-conjugated secondary antibodies. Enhanced chemiluminescence detection reagents (Thermo Fisher Scientific, Waltham, MA, USA) were applied for the color development of the PVDF membrane, and X-ray films were applied for exposure. The protein levels of target proteins were normalized to the internal control of β-actin.
RNA extraction and quantitative reverse-transcription polymerase chain reaction
TRIzol reagent (Thermo Fisher Scientific, USA) was involved to extract total RNA from the tissue samples. Rever Trace® quantitative polymerase chain reaction (qPCR) RT Kit (TOYOBO Co., Osaka, Japan) was applied according to the manufacturer's instructions. cDNA was synthesized by reverse transcription. Quantitative real-time (QRT)-PCR was performed with IQTMSYBR Green Supermix (Bio-Rad, Hercules, CA, USA). The relative levels of HMGB1/RAGE, LC3, Beclin-1, and PI3K in RCC tissues and adjacent nontumorous samples were calculated with the 2−ΔΔCT method. The primers were purchased from Sangon Biotech Co., Ltd (Shanghai). The sequence of primers was as follows: HMGB1 forward: 5′-AGTGCTCAGAGAGGTGGA-3′, HMGB1 reverse: TTTGGGAGGGATATAGGT; RAGE forward: 5GB1 forward: 5′-AGTGCTCAGAGAGGTGGA-3′, HMGB1 reverse: TTTGGGAGGGATATAGGT; RAGE forward: clear cell renal cell carcinomacarcnal cell carcarcCGCGAT-3rward: 5′-AGTGCTCAGAGAGGTGGA-3′, TACTGTTCT-3′, Beclin 1 reverse: 5′-TGTCTTCAATCTTGCCTT-3′; PI3K forward: 5′-CTCTAAACCCTGCTCATC-3GCTPI3K reverse: 5′-CTTGCGTAAATCATCCC-3′.
High-mobility group box 1 silencing and overexpression in the A498 and ACHN cell lines
The cells were seeded into 6-well plates (2.5 × 105 cells/well) and cultured overnight before transfection. A498 and ACHN cells were stably transfected with siRNAs directed against HMGB1 (HMGB1-siRNAs; GenePharma, Shanghai, China) or nontargeted control siRNA (GenePharma, Shanghai, China) with Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA, USA). The vector control and pcDNA3.1-HMGB1 plasmid were also transfected into cells with Lipofectamine 2000 according to the manufacturer's instructions. After 6 h of transfection, culture media containing the reagent mixture were removed and replaced with a fresh complete medium, and then the cells were applied for further experiments. Anti-RAGE neutralizing antibody (soluble RAGE [sRAGE]) was provided by Abcam (Cambridge, UK).
Immunofluorescence was performed on paraffin-embedded tissues. Briefly, sections were incubated with primary antibodies of RAGE, CD34, HMGB1, LC3, Beclin1, PI3K (Abcam, Cambridge, MA, USA) overnight. Sections were then washed with PBS and incubated with Alexa Fluor–conjugated secondary antibodies (Scigebio, Shanghai, China) and DAPI (Beyotime Biotech, Nantong, China). Images were taken with a NIKON ECLIPSE TI-SR photomicroscope (×200).
Statistical analysis was performed with SPSS 19.0 (SPSS, Chicago, IL, USA). Bar graphs were drawn with GraphPad Prism 7 (GraphPad Software, Inc., La Jolla, CA, USA). All the data were expressed as mean values ± standard deviation. A paired Student's t-test was applied to assess differences between two groups. P <0.05 indicated statistical significance. All the experiments were performed in triplicates.
| > Results|| |
The protein expression of high mobility group box 1/receptor for advanced glycation end-product, LC3, Beclin-1, and PI3K in ccRCC samples and adjacent normal tissues
The protein expression was evaluated in 12 pairs of histologically confirmed ccRCC samples and adjacent normal tissues. First, the expression of HMGB1/RAGE, LC3, Beclin-1, PI3K in clear cell RCC samples, and adjacent normal tissue were analyzed to explore the relationship between the expression of HMGB1/RAGE and autophagy. Growing evidence suggested that HMGB1/RAGE played an important role in the carcinogenesis process., Consistent with the results of previous reports, we found that the expression of HMGB1 in ccRCC samples (0.6138 ± 0.2394) was much higher than that of in the adjacent normal tissues [0.2247 ± 0.1772, [Figure 1]. Similarly, the expression of RAGE in ccRCC samples (0.5467 ± 0.1275) was much higher than that of in the adjacent normal tissues [0.2803 ± 0.1436, [Figure 1]. Similarly, the expression of LC3 in ccRCC samples (0.4994 ± 0.2334) was also much higher than that of in the adjacent normal tissues [0.1293 ± 0.0739, [Figure 1], as well as the expression of Beclin-1 (1.4572 ± 0.6087 compared with 0.6501 ± 0.1837) and PI3K (1.2629 ± 0.5330 compared with 0.7201 ± 0.2783).
|Figure 1: The expressions of high mobility group box 1/receptor for advanced glycation end-product, LC3, Beclin-1, PI3K were evaluated in clear cell renal cell carcinoma samples and adjacent normal tissues. (a) The expression of high mobility group box 1/receptor for advanced glycation end-product, LC3, Beclin-1, and PI3K in clear cell renal cell carcinoma samples and adjacent normal tissues were detected by sodium dodecyl sulfate-polyacrylamide gel electrophoresis/immunoblotting with corresponding antibodies. GAPDH was applied as an internal control. These experiments were repeated in triplicate. (b) Protein expression levels (relative to GAPDH) in clear cell renal cell carcinoma samples and adjacent normal tissues were determined. The data were expressed as mean ± standard deviation for three replicates|
Click here to view
The mRNA expressions of high-mobility group box 1/receptor for advanced glycation end-product, LC3, Beclin-1, and PI3K in ccRCC samples and adjacent normal tissues
The mRNA expression of HMGB1/RAGE, LC3, Beclin-1, and PI3K was evaluated with qRT-PCR. We found that the mRNA expression of HMGB1 in ccRCC samples (1.1978 ± 0.8004) was higher than that of in the adjacent normal tissues [0.8093 ± 0.8768, [Figure 2]. Similarly, the expression of RAGE in ccRCC samples (1.7319 ± 0.9643) was much higher than that of in adjacent normal tissues [0.8759 ± 0.7078, [Figure 2]. The expression of LC3 in ccRCC samples (1.5504 ± 0.6506) was also much higher than that of in adjacent normal tissues [0.7423 ± 0.3899, [Figure 1], as well as the expression of Beclin-1 (1.4572 ± 0.6087 compared with 0.6501 ± 0.1837) and PI3K (1.2629 ± 0.5330 compared with 0.7201 ± 0.2783).
|Figure 2: The mRNA levels of high mobility group box 1/receptor for advanced glycation end-product, LC3, Beclin-1, and PI3K in clear cell RCC samples and adjacent normal tissues were detected by quantitative real-time polymerase chain reaction. Total RNA from the tissue samples was extracted with TRIzol reagent. cDNA was synthesized by reverse transcription using Rever Trace® quantitative polymerase chain reaction RT Kit. Then, the relative levels of high mobility group box 1/receptor for advanced glycation end-product, LC3, Beclin-1 and PI3K in renal cell carcinoma and adjacent nontumorous were calculated with the 2−ΔΔCT method *P < 0.05, **P < 0.01|
Click here to view
The expression of high mobility group box 1/receptor for advanced glycation end-product, LC3, Beclin-1, and PI3K in ccRCC samples and adjacent normal tissue by immunofluorescence
The relationship of HMGB1/RAGE and autophagy was also confirmed with immunofluorescence. Consistent with the previous results, HMGB1/RAGE expression in the ccRCC samples was much higher than that of in the adjacent normal tissues as shown in [Figure 3]. We also found that the expression of the autophagic protein LC3, Beclin-1, PI3K in ccRCC samples was much higher than that of in adjacent normal tissues.
|Figure 3: Representative photographs of immunofluorescence staining of high mobility group box 1/receptor for advanced glycation end-product, LC3, Beclin-1 and PI3K in clear cell renal cell carcinoma samples and adjacent normal tissues. The tumor and normal tissues of patients were stained with high mobility group box 1/receptor for advanced glycation end-product, LC3, Beclin-1, and PI3K. The photographs were taken at the magnifications of ×200|
Click here to view
The regulation of receptor for advanced glycation end-product and autophagic protein expression with high-mobility group box 1 in human renal cell carcinoma cell lines
A key regulator of autophagy in the TME was Damage Associated Molecular Pattern molecules, such as HMGB1 and its receptor RAGE., Therefore, the interaction of HMGB1 and RAGE was analyzed with qRT-PCR. We found that, after the knockdown of the HMGB1, down-regulated the mRNA expression of RAGE, and autophagic protein LC3 and Beclin1 would be down-regulated shown in [Figure 4]a and [Figure 4]b. While the level of RAGE would be up-regulated with the overexpressed HMGB1 shown in [Figure 4]a and [Figure 4]b. Moreover, the mRNA expression of autophagic protein LC3 and Beclin-1 was also remarkably upregulated with the overexpression of HMGB1.
|Figure 4: High mobility group box 1 regulated receptor for advanced glycation end-product and autophagic protein mRNA expression in human renal cell carcinoma cell lines. (a) The expression of high mobility group box 1, receptor for advanced glycation end-product, LC3, and Beclin1 in the A498 cell line were analyzed by quantitative real-time polymerase chain reaction. (b) The expression of high mobility group box 1, receptor for advanced glycation end-product, LC3, and Beclin1 in the ACHN cell line were analyzed by quantitative real-time polymerase chain reaction. Data were presented as mean ± standard deviation for three independent experiments. *P < 0.05, **P < 0.01, versus Con-siRNA group; ##P < 0.01, versus Con-Vec group; ^^P < 0.01, versus receptor for advanced glycation end-product group|
Click here to view
The relationships of HMGB1, RAGE, and LC3 were also further analyzed with immunofluorescence. As shown in [Figure 5], there were decreased expression levels of LC3 and RAGE in the HMGB1-siRNA1 group, the expression levels of LC3 and RAGE were up-regulated with the overexpression of HMGB1. In addition, the HMGB1-Vec+sRAGE group showed an increased expression level of LC3, while it was decreased compared to that of in the sRAGE group. These results suggested that HMGB1 played an important role in the RAGE and autophagic protein expression in RCC cells.
|Figure 5: High mobility group box 1 regulated receptor for advanced glycation end-product and LC3 expression in human renal cell carcinoma cell lines. The expression of LC3 (red) and receptor for advanced glycation end-product (green) in the (a) A498 cell line (b) ACHN cell line were examined by immunofluorescence analysis and observed with a confocal microscope. DAPI was a blue tint to the nucleus. The photographs were taken at the magnifications of ×200. The representative result was shown from three repeats with a similar pattern|
Click here to view
| > Discussion|| |
Originally, RAGE was defined as a RAGE. Then, it was found to be the receptor of many other molecules involved in innate immunity, including amyloid-β peptide, the S100 family of proteins, and HMGB-1. Emerging reports have demonstrated the important roles of RAGE in the pathogenesis of multiple human physical disorders including malignant tumors., In the past a few years, RAGE was found to make important effects in the RCC progression. RAGE was proved to be a potential prognostic biomarker for RCC. In this research, RAGE was also found to be upregulated in ccRCC tumor tissues compared with that of in adjacent normal tissue.
HMGB1 was a conserved protein with various physiological function with the main receptors of RAGE and TLR. RAGE and TLR were confirmed to be on the surface of endothelial cells and immune system cells. Once being released to the extracellular space, HMGB1 would become a proinflammatory cytokine, then activate the formation of new blood microvessels, improve the cell metastasis, enhance the inflammatory conditions, and regulate cell growth. HMGB1 protein also played an important role in regenerating the impaired tissues and stimulating autophagy. HMGB1 played a potential role in anticancer therapy. In the immunohistochemical results, HMGB1 expression in the pathological samples of patients confirmed that ccRCC was related to the PT1b classification and tumor grade., In ccRCC, there was a methylation of HMGB1 at lysine 112, which affected its binding capacity with DNA, as well as mediating its translocation. It also reported that the development and progression of ccRCC would be promoted with HMGB1 through the activation of ERK1/2, which was partially regulated by RAGE. Consistent with the previous results, our data confirmed that the expression level of HMGB1 was higher in the ccRCC tumor tissues compared with that of in the adjacent normal tissues.
As a nonchromosomal DNA binding protein, HMGB1 has taken part in a variety of cellular biological processes, including cell differentiation, cell autophagy, and cell invasion., HMGB1 also played important roles in the inflammatory reactions through regulating the expression of NFκB, as well as inducing the upregulation of c-myc which contributed to tumor malignancies. For the autophagy, HMGB1 was involved at several levels. First, HMGB1 mediated the expression of heat shock protein β-1, which was a key player in the dynamic intracellular trafficking during autophagy and mitophagy. Moreover, HMGB1 could destroy the Beclin-1-B cell lymphoma-2 complex and activate autophagy through the interaction with Beclin-1. Therefore, the autophagic protein LC3, Beclin-1, and PI3K were investigated in this study. Our data demonstrated that the expression levels of autophagic proteins were also upregulated in ccRCC tumor tissues compared with those of in adjacent normal tissues. Through the knockdown and overexpression of HMGB1/RAGE, it also confirmed the critical roles of HMGB1/RAGE in the regulation of autophagic protein.
| > Conclusion|| |
Autophagic protein, HMGB1, and its receptor RAGE were increased in ccRCC tumor tissues. We suggested that the interaction between HMGB1 and RAGE initiated signaling such as ERK1/2 phosphorylation, NF-kB, and MAPK, which contributed to autophagy in ccRCC. These findings collectively implicated that HMGB1 and RAGE might serve as a therapeutic target for future treatment on ccRCC. As far as we know, the current RAGE-targeted antineoplastic therapies involved the treatments with small molecule inhibitors,, sRAGE and nonviral gene delivery vectors. Nowadays, several inhibitors of HMGB1 have been investigated, which could be applied in anticancer therapy.
These RAGE suppressants and HMGB1 inhibitors play important roles in the regulation of autophagy, which might be potential candidate drugs in inhibiting cancer recurrence during chemotherapy.
We would like to acknowledge special thanks to the faculty of the Department of Pathology, the Fifth Hospital of Sijiazhuang.
Financial support and sponsorship
This study was supported by Wenzhou Municipal Science and Technology Bureau (Y20160032, Y20160127), Zhejiang medical and health science and technology project (2017KY454).
Conflicts of interest
There are no conflicts of interest.
| > References|| |
Kurts C, Panzer U, Anders HJ, Rees AJ. The immune system and kidney disease: Basic concepts and clinical implications. Nat Rev Immunol 2013;13:738-53.
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
Webber K, Cooper A, Kleiven H, Yip D, Goldstein D. Management of metastatic renal cell carcinoma in the era of targeted therapies. Intern Med J 2011;41:594-605.
Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al.
Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27:v58-68.
Xie J, Méndez JD, Méndez-Valenzuela V, Aguilar-Hernández MM. Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell Signal 2013;25:2185-97.
Ramasamy R, Yan SF, Schmidt AM. RAGE: Therapeutic target and biomarker of the inflammatory response – The evidence mounts. J Leukoc Biol 2009;86:505-12.
Neumann E, Engelsberg A, Decker J, Störkel S, Jaeger E, Huber C, et al.
Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: Candidates for T-cell-based immunotherapies? Cancer Res 1998;58:4090-5.
Liu X, Hao Y, Fan T, Nan K. Application of intelligent algorithm in the optimization of novel protein regulatory pathway: Mechanism of action of gastric carcinoma protein p42.3. J Cancer Res Ther 2016;12:650-6.
Fuentes MK, Nigavekar SS, Arumugam T, Logsdon CD, Schmidt AM, Park JC, et al.
RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis Colon Rectum 2007;50:1230-40.
Takada M, Koizumi T, Toyama H, Suzuki Y, Kuroda Y. Differential expression of RAGE in human pancreatic carcinoma cells. Hepatogastroenterology 2001;48:1577-8.
Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, Uemura H, et al.
Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 2005;64:92-100.
Xu XC, Abuduhadeer X, Zhang WB, Li T, Gao H, Wang YH, et al.
Knockdown of RAGE inhibits growth and invasion of gastric cancer cells. Eur J Histochem 2013;57:e36.
Yaser AM, Huang Y, Zhou RR, Hu GS, Xiao MF, Huang ZB, et al.
The role of receptor for advanced glycation end products (RAGE) in the proliferation of hepatocellular carcinoma. Int J Mol Sci 2012;13:5982-97.
Elangovan I, Thirugnanam S, Chen A, Zheng G, Bosland MC, Kajdacsy-Balla A, et al.
Targeting receptor for advanced glycation end products (RAGE) expression induces apoptosis and inhibits prostate tumor growth. Biochem Biophys Res Commun 2012;417:1133-8.
Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, et al.
Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000;405:354-60.
Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, et al.
RAGE (Receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med 2009;7:17.
Smolarczyk R, Cichoń T, Jarosz M, Szala S. HMGB1 – Its role in tumor progression and anticancer therapy. Postepy Hig Med Dosw (Online) 2012;66:913-20.
Origlia N, Arancio O, Domenici L, Yan SS. MAPK, beta-amyloid and synaptic dysfunction: The role of RAGE. Expert Rev Neurother 2009;9:1635-45.
Goodwin GH, Sanders C, Johns EW. A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur J Biochem 1973;38:14-9.
Kenific CM, Debnath J. Cellular and metabolic functions for autophagy in cancer cells. Trends Cell Biol 2015;25:37-45.
Liu XD, Zhu H, DePavia A, Jonasch E. Dysregulation of HIF2α and autophagy in renal cell carcinoma. Mol Cell Oncol 2015;2:e965643.
Riehl A, Németh J, Angel P, Hess J. The receptor RAGE: Bridging inflammation and cancer. Cell Commun Signal 2009;7:12.
Kang R, Tang D, Lotze MT, Zeh HJ 3rd
. AGER/RAGE-mediated autophagy promotes pancreatic tumorigenesis and bioenergetics through the IL6-pSTAT3 pathway. Autophagy 2012;8:989-91.
Kang R, Tang D, Lotze MT, Zeh HJ 3rd
. RAGE regulates autophagy and apoptosis following oxidative injury. Autophagy 2011;7:442-4.
Rojas A, Figueroa H, Morales E. Fueling inflammation at tumor microenvironment: The role of multiligand/RAGE axis. Carcinogenesis 2010;31:334-41.
Guo Y, Xia P, Zheng JJ, Sun XB, Pan XD, Zhang X, et al.
Receptors for advanced glycation end products (RAGE) is associated with microvessel density and is a prognostic biomarker for clear cell renal cell carcinoma. Biomed Pharmacother 2015;73:147-53.
Takeuchi T, Sakazume K, Tonooka A, Zaitsu M, Takeshima Y, Mikami K, et al.
Cytosolic HMGB1 expression in human renal clear cell cancer indicates higher pathological T classifications and tumor grades. Urol J 2013;10:960-5.
Wu F, Zhao ZH, Ding ST, Wu HH, Lu JJ. High mobility group box 1 protein is methylated and transported to cytoplasm in clear cell renal cell carcinoma. Asian Pac J Cancer Prev 2013;14:5789-95.
Lin L, Zhong K, Sun Z, Wu G, Ding G. Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma. J Cancer Res Clin Oncol 2012;138:11-22.
Srinivasan M, Banerjee S, Palmer A, Zheng G, Chen A, Bosland MC, et al.
HMGB1 in hormone-related cancer: A potential therapeutic target. Horm Cancer 2014;5:127-39.
Tang D, Kang R, Cheh CW, Livesey KM, Liang X, Schapiro NE, et al.
HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 2010;29:5299-310.
Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, et al.
Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001;50:2792-808.
Tang D, Kang R, Livesey KM, Kroemer G, Billiar TR, Van Houten B, et al.
High-mobility group box 1 is essential for mitochondrial quality control. Cell Metab 2011;13:701-11.
Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P, et al.
Endogenous HMGB1 regulates autophagy. J Cell Biol 2010;190:881-92.
Brodeur MR, Bouvet C, Bouchard S, Moreau S, Leblond J, Deblois D, et al.
Reduction of advanced-glycation end products levels and inhibition of RAGE signaling decreases rat vascular calcification induced by diabetes. PLoS One 2014;9:e85922.
Sabbagh MN, Agro A, Bell J, Aisen PS, Schweizer E, Galasko D, et al.
PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord 2011;25:206-12.
Giron-Gonzalez MD, Morales-Portillo A, Salinas-Castillo A, Lopez-Jaramillo FJ, Hernandez-Mateo F, Santoyo-Gonzalez F, et al.
Engineered glycated amino dendritic polymers as specific nonviral gene delivery vectors targeting the receptor for advanced glycation end products. Bioconjug Chem 2014;25:1151-61.
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5]